五积散加减联合Ca² 阻断剂治疗寒邪凝滞型高血压的临床疗效分析  

Five Product Dispersion Plus and Minus Combined with Ca2 Blocking Agent for Cold Evil Stagnation Type Clinical Efficacy Analysis of Hypertension

作　　者：喻泽篇 汪朝景 秦娟娟 陆廷飞 

机构地区：[1]安顺市西秀区旧州次医疗中心,贵州 安顺 [2]贵州中医药大学第一临床医学院,贵州 贵阳

出　　处：《医学诊断》2024年第1期132-136,共5页Medical Diagnosis

摘　　要：目的:以五积散加减联合Ca2 阻断剂作为寒邪凝滞型高血压的治疗方案,进而探究高血压的中西医临床治疗效果。方法:实验对象为2020年9月~2022年6月期间医治的120名寒邪凝滞型高血压(HBP)病人,以1至120号对这些病人排序,其中1至60号归入研究组,用五积散加减合Ca2 阻断剂治疗,而后61到120号定为对照组,仅行Ca2 阻断剂干预,2组病人干预结束,对双方疗效展开对比观察。结果:在有效治疗率上,研究组呈91.2%,对照组呈76.7%,前者相较后者明显偏高,双方表现出显著不同(P < 0.05);在血压(BP)水平上,相较未干预时,2组干预后皆未表现出显著不同,干预后2组皆有所改善,同时就改善效果而言,研究组相较对照组更加明显(P < 0.05)。结论:对于HBP病人行西药 五积散加减治疗,可获得显著的临床疗效,同时具备可靠性、安全性。Objective: To use Ca2 blocking agent as the treatment scheme of cold evil coagulation type hypertension, and then explore the traditional Chinese and western medicine of hypertension treatment effect. Methods: The subjects were 120 patients with cold coagulation hypertension (HBP) treated from September 2020 to June 2022. These patients were sorted from numbers 1 to 120, with numbers 1 to 60 placed in the study group, treated with Ca2 blockers, and then number 61 to 120. The number was designated as the control group, with only Ca2 blocker intervention. After the intervention in 2 groups, the efficacy of both patients was compared. Results: In the effective treatment in terms of rate, the study group was 91.2%, and the control group was 76.7%. The former was significantly higher than the latter, and the two sides showed significantly different values (P < 0.05);At the blood pressure (BP) level, none of the two groups was significantly different after the intervention compared with the no intervention, but both of the two groups improved after the intervention in terms of effect, the study group was more obvious than the control group (P < 0.05). Conclusion: For HBP patients with western medicine pentaplus minus treatment can get significant clinical efficacy, with reliability and safety.

关 键 词：五积散加减 寒邪凝滞型 发汗解表 高血压 临床疗效 Ca² 阻断剂 

分 类 号：R54[医药卫生—心血管疾病]